A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study of the Efficacy, Safety, and Tolerability of ITI-1284 in Patients With Agitation Associated With Alzheimer's Dementia
Latest Information Update: 26 Feb 2025
At a glance
- Drugs Lumateperone (Primary)
- Indications Agitation
- Focus Therapeutic Use
- Sponsors Intra-Cellular Therapies
- 23 Oct 2024 Status changed from planning to recruiting.
- 09 Aug 2024 New trial record
- 07 Aug 2024 According to an Intra-Cellular Therapies media release, company anticipate initiate enrollment in this trial shortly.